Trial
NCT04074330
A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin Lymphoma
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Takeda
Collaborators
—
Condition
Lymphoma, Non-Hodgkin
Intervention
TAK-981
Why stopped
Enrolment Challenges
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-06-14